A Phase 1, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of LCAR-C18S, an CAR-T Cell Therapy Targeting Claudin18.2 in Patients With Advanced Solid Tumors is a PHASE1 clinical asset sponsored by Shanghai East Hospital in Solid Tumors, Adult. SEO and diligence focus: LCAR-C18S cells, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.